Suppr超能文献

与非常老年非黑素瘤皮肤癌患者预期寿命有限相关的合并症评分。

Comorbidity scores associated with limited life expectancy in the very elderly with nonmelanoma skin cancer.

机构信息

Robert Wood Johnson Medical School, New Brunswick, New Jersey.

Memorial Sloan Kettering Cancer Center, New York, New York.

出版信息

J Am Acad Dermatol. 2018 Jun;78(6):1119-1124. doi: 10.1016/j.jaad.2017.12.048. Epub 2017 Dec 27.

Abstract

BACKGROUND

There is controversy regarding treatment of nonmelanoma skin cancer (NMSC) in very elderly individuals, with some suggesting that this population may not live long enough to benefit from invasive treatments. Tools to assess limited life expectancy (LLE) exist, but performance in the population of very elderly individuals with NMSC has not been well defined.

OBJECTIVE

Define comorbidity scores associated with LLE in very elderly individuals presenting for management of NMSC.

METHODS

A retrospective review of 488 patients age 85 or older presenting for NMSC management between July 1999 through December 2014 was performed. Comorbidities were scored by using the Adult Comorbidity Evaluation-27 (ACE-27) and age-adjusted Charlson comorbidity index (ACCI). Dates of death, follow-up, and overall survival were determined.

RESULTS

ACE-27 and ACCI scores were associated with overall survival; at scores of 3 and 7+, respectively, both were associated with less than 50% survival at 4 years. Patients who underwent Mohs micrographic surgery survived a median of 20 months longer than patients who did not.

LIMITATIONS

Retrospective study design and referral bias.

CONCLUSIONS

ACE-27 and ACCI scores predicted LLE. The cohort presenting for Mohs micrographic surgery had improved survival, despite similar intercohort comorbidity. This suggests that additional factors contributed to survival and that age and comorbidities alone are inadequate for making NMSC treatment decisions in very elderly individuals.

摘要

背景

对于非常高龄个体的非黑色素瘤皮肤癌(NMSC)的治疗存在争议,一些人认为该人群可能活不到从侵袭性治疗中获益的时间。存在评估有限预期寿命(LLE)的工具,但尚未很好地定义 NMSC 极高龄人群中的表现。

目的

确定与接受 NMSC 治疗的超高龄个体的 LLE 相关的合并症评分。

方法

对 1999 年 7 月至 2014 年 12 月期间因 NMSC 管理而就诊的 488 名 85 岁或以上的患者进行了回顾性研究。使用成人合并症评估-27(ACE-27)和年龄调整 Charlson 合并症指数(ACCI)对合并症进行评分。确定了死亡、随访和总生存的日期。

结果

ACE-27 和 ACCI 评分与总生存相关;评分分别为 3 和 7+时,两者在 4 年内的生存率均低于 50%。接受 Mohs 显微外科手术的患者的中位生存时间比未接受手术的患者长 20 个月。

局限性

回顾性研究设计和转诊偏倚。

结论

ACE-27 和 ACCI 评分预测 LLE。尽管存在相似的组间合并症,但接受 Mohs 显微外科手术的患者的生存率有所提高。这表明生存的其他因素起了作用,而且年龄和合并症本身不足以用于做出非常高龄个体的 NMSC 治疗决策。

相似文献

引用本文的文献

6
Non-Melanoma Skin Cancers in the Older Patient.老年患者的非黑素瘤皮肤癌。
Curr Oncol Rep. 2019 Jul 29;21(9):79. doi: 10.1007/s11912-019-0828-9.

本文引用的文献

1
United States Life Tables, 2013.《2013年美国生命表》
Natl Vital Stat Rep. 2017 Apr;66(3):1-64.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验